“Vitiligo Pipeline” report has been added to DelveInsight
Vitiligo Pipeline analysis across different stages of development (Phase III & Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities
Download free sample copy– https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight
About Vitiligo Disease
Defines Vitiligo as a condition in which the skin loses melanin, the pigment that determines the color of skin, hair, and eyes. If the cells that do not produce melanin die or no longer produce melanin, slowing growing white patches of irregular shapes appear on the skin. The typical lesions on the skin can be defined as milky white, non-scaly macules that are present with distinct margins.
Researchers have identified several forms of Vitiligo. Generalized Vitiligo (also called non-segmental Vitiligo), which is the most common form, involves loss of pigment (depigmentation) in patches of skin all over the body. Another form called Segmental Vitiligo (also known as unilateral or localized Vitiligo) is associated with smaller patches of depigmented skin that appear on one side of the body in a limited area; this occurs in about 10% of affected individuals. The localized type is further subdivided into focal, segmental, and mucosal subtypes, while the generalized type is subdivided into acrofacial, vulgaris, and universal subtypes. An overlap of various types can be classified as ‘mixed type’.
The main symptoms of Vitiligo are flat, white spots or patches on the skin. Gradually the patches become completely white. Sometimes the center of a patch may be white with pale skin around it. Other signs include: premature whitening or graying of the hair on your scalp, eyelashes, eyebrows or beard, loss of color in the tissues that line the inside of your mouth (mucous membranes), loss or change in color of the inner layer of your eye (retina). Although any part of your body may be affected by vitiligo, depigmentation usually first develops on sun-exposed areas of your skin, such as your hands, feet, arms, face and lips.
The diagnosis of vitiligo is generally made clinically through the appearance of reduced or lost pigmentation of the skin in a typical distribution. The differential diagnosis of vitiligo is broad and includes inflammatory, postinflammatory, neoplastic, and primary pigmentary genetic disorders
The treatments include phototherapy, topical and systemic immunosuppressants, and surgical techniques, which together may help in halting the disease, stabilizing depigmented lesions and stimulating repigmentation. Choice of treatment depends on several factors including: the subtype of the disease, the extent, distribution and activity of disease as well as the patient’s age, phototype, effect on quality of life and motivation for treatment.
Emerging drugs included in the report
- ARQ-252: Arcutis Biotherapeutics
- Ruxolitinib: Incyte Corporation
Vitiligo Pipeline: Report Highlights
- In the coming years, Vitiligo market is set to change due to the rising awareness of the disease, and incremental healthcare spending across the world; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
- The companies and academics are working to assess challenges and seek opportunities that could influence Vitiligo R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
- Major players are involved in developing therapies for Vitiligo. Launch of emerging therapies will significantly impact the Vitiligo market
- A better understanding of disease pathogenesis will also contribute to the development of novel therapeutics for Vitiligo
- Our in-depth analysis of the pipeline assets across different stages of development (Phase III and Phase II), different emerging trends and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities
Request free sample copy- https://www.delveinsight.com/sample-request/vitiligo-pipeline-insight
Following is the table of content of Vitiligo Pipeline
- Report Introduction
- Vitiligo Current Treatment Patterns
- Vitiligo – DelveInsight’s Analytical Perspective
- Therapeutic Assessment
- Vitiligo Late Stage Products (Phase-III)
- Vitiligo Mid Stage Products (Phase-II)
- Early Stage Products (Phase-I)
- Pre-clinical Products and Discovery Stage Products
- Inactive Products
- Dormant Products
- Vitiligo Discontinued Products
- Vitiligo Product Profiles
- Vitiligo Key Companies
- Vitiligo Key Products
- Dormant and Discontinued Products
- Vitiligo Unmet Needs
- Vitiligo Future Perspectives
- Vitiligo Analyst Review
- Report Methodology
Vitiligo Pipeline: Key Questions
- What are the current options for Vitiligo treatment?
- How many companies are developing therapies for the treatment of Vitiligo ?
- What are the principal therapies developed by these companies in the industry?
- How many therapies are developed by each company for the treatment of Vitiligo ?
- How many Vitiligo emerging therapies are in early-stage, mid-stage, and late stage of development for the treatment of Vitiligo ?
- Out of total pipeline products, how many therapies are given as a monotherapy and in combination with other therapies?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, and major licensing activities that will impact Vitiligo market?
- Which are the dormant and discontinued products and the reasons for the same?
- What is the unmet need for current therapies for the treatment of Vitiligo ?
- What are the recent novel therapies, targets, mechanisms of action and technologies developed to overcome the limitation of existing Vitiligo therapies?
- What are the clinical studies going on for Vitiligo and their status?
- What are the results of the clinical studies and their safety and efficacy?
- What are the key designations that have been granted for the emerging therapies for Vitiligo ?
- How many patents are granted and pending for the emerging therapies for the treatment of Vitiligo?